T-wave Alternans in Sudden Cardiac Death | GE Healthcare

Webinar recording of T-wave Alternans in Sudden Cardiac Death presented by Dr Tuomo Nieminen M.D.

Efficient methods to prevent SCD have certain adverse effects and are costly. The pump function of the left ventricle is the main method of assessing the risk of this disease. T-wave alternans, a marker of instable repolarisation phase of the cardiac cycle, is a promising parameter to be used in the clinical practice for stratifying the risk of SCD.

A major randomised clinical trial using T-wave alternans and implantable cardioverter difibrillators (ICD) is ongoing and is discussed in this session. #GEHealthcare #GeneralElectric


Learn more about GE Healthcare

About GE Healthcare:
As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform.

With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

We embrace a culture of respect, transparency, integrity and diversity.

T-wave Alternans in Sudden Cardiac Death | GE Healthcare